Company overview cardiol therapeutics the deep dive ledderhose disease images

Overall, we believe that Cardiol Therapeutics (C$144M Market Cap) could turn into a market darling with the scale to ledderhose disease images produce pure-quality pharmaceutical CBD, at lower costs than the rest of the market, resulting in strong margins. They also have interesting drug development programs that could make ledderhose disease images them quickly comparable to companies such as GW Pharma (C$6.79B Market Cap) and MyoKardia Inc (C$2.97B Market Cap). History of Cardiol

Cardiol was founded in late 2016 by David Elsley (CEO and President), Dr. Anthony Bolton (Director of Research), Dr. Eldon Smith (Chairman and CMO), and Terry Lynch (Director), who have decades of experience in developing companies in the ledderhose disease images medical space. After a study published in the Journal of the American ledderhose disease images College of Cardiology showed the promise for CBD as a ledderhose disease images potential treatment for heart failure, the team established an organization and research network focused on ledderhose disease images developing the most advanced form of this important medicine and ledderhose disease images new innovative ways to deliver it to patients and consumers.

Cardiol has developed unique manufacturing expertise in the production of ledderhose disease images pharmaceutical cannabinoids in support of its 2019 commercial product launch ledderhose disease images and its nanotherapeutics program in heart failure. Cardiol’s lead pharmaceutical cannabidiol product, CardiolRx, will address a significant proportion of the total medicinal cannabinoid ledderhose disease images market. The company intends to commercialize its CardiolRx formulation during H2/2019 in two concentrations – 50 mg/ml CBD and 100 mg/ml CBD.

Published third-party research has shown that cannabidiol reduces inflammatory activation of ledderhose disease images the endothelial lining of blood vessels and aids endothelial vasorelaxation, resulting in improved blood flow. Cannabidiol has also been shown to attenuate a number of ledderhose disease images measures of inflammation in models of diabetes, a common co-morbidity in heart failure patients, and to reduce myocardial fibrosis in a model of inflammatory ledderhose disease images heart disease.

CsA is an immunosuppressant more commonly used for the prevention ledderhose disease images of organ transplant rejection, including for heart transplantation. The current evidence suggests that the mechanism of CsA relates ledderhose disease images to its activity at the mitochondrial membrane, specifically at pores in the membrane (the mitochondrial permeability transition pores, MPTP), where the action of CsA reduces the rupture of the ledderhose disease images mitochondrial membrane. Rupture of the mitochondrial membrane leads to cell death, and, in the heart, death of heart muscle cells (cardiomyocytes). Cardiomyocyte cell death is an important component of the pathology ledderhose disease images of heart failure causing largely irreparable damage and is therefore ledderhose disease images a key clinical target in patients with heart failure.

Glioblastoma multiforme (GBM) is a fast-growing tumor that develops from star-shaped glial cells (astrocytes and oligodendrocytes) that support the health of the nerve cells within the ledderhose disease images brain. It is the most malignant and deadly form of cancer ledderhose disease images of the central nervous system in humans. Death results from the rapid, aggressive, and infiltrative growth of GBM cells in the brain.

Cardiol’s patent-pending cancer therapeutic platform envisages the use of certain immune ledderhose disease images modulators to stimulate cells of the immune system to target ledderhose disease images tumors. Tumor cell killing can ultimately be achieved in the body ledderhose disease images by activated white blood cells, such as tumor-infiltrating lymphocytes (TILs) and lymphokine-activated killer (LAK) cells; however, many tumors have an immunosuppressive environment to shield the tumor ledderhose disease images from the patient?s immune system. Cardiol anticipates that cannabinoids may modify this immunosuppressive ?shield?.

In the event CBD sales can clear anything close to ledderhose disease images a penetration rate north of 5% at $20/month/customer, pharmacies will treat CBD as a major priority. It would not be a wild assumption to believe that ledderhose disease images they will prefer a 100% pure pharmaceutical CBD product that can retail at a cost ledderhose disease images advantage to competitors. Cardiol has hired personnel to help them target the top ledderhose disease images pharmacy chains in Canada.

“Recently we appointed Tom Moffatt to head our commercial operations. Tom has over 25 years’ experience in pharmacy operations, primarily with Shoppers Drug Mart, Canada’s largest pharmacy infrastructure. Shoppers Drug Mart is owned by Loblaw Companies Ltd. Shoppers Drug Mart and Loblaw between them own over 1850 ledderhose disease images pharmacies nationally. Through this network of pharmacies, they can promote Medical Cannabis via the Shoppers Drug Mart ledderhose disease images website for the distribution of cannabinoids. As we complete our manufacturing scale-up process to support the commercial launch of our CardiolRx ledderhose disease images brand in H2 2019, Tom’s experience will prove invaluable in managing negotiations with potential ledderhose disease images distribution partners, including pharmacies.” – David Elsley, CEO; Interview w/The Deep Dive

It is difficult to find a direct comparable to Cardiol. If the expectation is that pharmacies will have a preference ledderhose disease images to carry 100% pure CBD, it is likely that Cardiol will be a market leader ledderhose disease images in CBD in their three target markets: Canada, Mexico, and Germany. They will not be able to introduce CardiolRx in the ledderhose disease images U.S. at the present time as the current regulations do not ledderhose disease images allow pharmaceutically-produced CBD, but this could change in the future as regulations governing ledderhose disease images CBD continue to evolve rapidly. Charlotte’s Web

Charlotte’s Web sells a high CBD, low-THC, cannabis strain marketed as a dietary supplement under federal law ledderhose disease images of the US. The company is the market leader in store bought CBD ledderhose disease images products. In the company’s Fall 2018 Prospectus , the company stated their market share was approximately 14% (based on 2017 revenues in an estimated US$287 million hemp CBD market). Outside of Charlotte?s Web and CV Sciences, the US CBD market is fragmented with no other large ledderhose disease images players.

MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious ledderhose disease images and neglected rare cardiovascular diseases. MyoKardia is currently enrolling patients in a Phase 3 to ledderhose disease images evaluate the efficacy and safety of mavacamten for the treatment ledderhose disease images of symptomatic obstructive hypertrophic cardiomyopathy.

Generally, the purpose of phase I clinical trials is to determine ledderhose disease images if a drug or procedure is safe. Given that cannabidiol has an excellent safety profile, we feel it is quite likely Cardiol will enter phase ledderhose disease images II clinical trials for CTX01 and CRxIMT within the next ledderhose disease images 6–12 months, making MyoKardia an interesting comparable to Cardiol. A Very Impressive Management Team

Previously, Mr. Elsley founded Vasogen Inc., a biotechnology company focused on the research and commercial development ledderhose disease images of novel therapeutics for the treatment of heart failure and ledderhose disease images other inflammatory conditions. Vasogen went public on the TSX and the Nasdaq, raising over $200 million to support corporate development and reached a market ledderhose disease images capitalization of over US$ 1 billion.

Mr. Waddick has 30+ years of experience in financial and executive roles in the ledderhose disease images biotechnology and energy industries.ÿAs Executive Vice President and Chief Financial Officer for a ledderhose disease images private Ontario energy company, he implemented two corporate restructurings, drove substantial earnings growth, and significantly reduced cost of capital and debt levels. He also served for over 10 years as the COO ledderhose disease images and CFO of Vasogen Inc.

Cardiol has partnerships with recognized global leaders in pharmaceutical manufacturing. They have world-class research and development partners and IP that could make ledderhose disease images them a global leader in pharmaceutical CBD. Something we talk about at length at The Deep Dive ledderhose disease images is how few companies there are that pass a basic ledderhose disease images three-question invest-ability test: 1) are they a great operator? 2) are they shareholder friendly? and 3) are they strong capital allocators? We feel that Cardiol strongly meets all these criteria and ledderhose disease images feel that as more investors discover their story, their share price should react positively.